Malaria and trypanosomiasis are vector-borne protozoal diseases which disproportionately affect the poor. Both give rise to immense human suffering; malaria exerts its effect directly on human health, while trypanosomiasis causes damage largely though its effect on the health and productivity of the livestock on which so many poor people depend. These diseases both have multifaceted and poorly understood mechanisms of pathogenesis, combined with relatively complex life cycles characterised by multiple stages in both insect vector and mammalian host. In both cases, there is a dramatic effect of host genotype on disease progression. This effect is apparent in both the human and cattle hosts and among inbred mouse strains. This provides an opportunity to use the mouse to probe the mechanisms underlying resistance or susceptibility to pathology. The availability of high-density linkage maps, the genome sequence and transcriptomics tools has transformed the power of the mouse to illuminate such fundamental aspects of the host-parasite interaction.
INTRODUCTION
The mouse has become an essential tool for studying biological processes in mammals. Of particular importance in the study of the host response to infectious disease is understanding why some naturally occurring genotypes are dramatically more sensitive to disease than are others. How far the existing mouse strains are true models of resistance and sensitivity in humans or cattle is debatable. The ways in which these strains differ in terms of disease progression will be discussed below; however, they unquestionably provide an opportunity to identify host factors that influence disease progression. In this respect, the naturally occurring variants are quite different from N-ethyl-N-nitrosourea (ENU) mutants, knockouts or transgenics, which invariably involve single genes with catastrophic loss (or gain) of function.
Malaria
The genetics of the malaria parasite and its host have been extensively studied in murine systems. A mapping experiment using the human parasite requires the use of mosquitoes to infect chimpanzees with Plasmodium falciparum gametocytes. Murine malarias mean that it is possible to work entirely in the mouse -a far more tractable and cost-effective model. Such studies have focused on increasing our understanding of the parasite, including the development of drug resistance, antigenic variation and erythrocytic invasion pathways. Mouse models have also been extensively used to dissect the host response to disease, including the innate and adaptive immune responses.
Malaria is endemic in more than 90 countries, comprising most of the developing world. It is estimated that malaria, caused by the haemoprotozoan parasite Plasmodium, infects 300-500 million people worldwide, and kills an estimated 2-3 million people annuallymainly young children and pregnant women. In spite of the one-time hope that malaria would be eradicated, this disease is still the world's most common and severe parasitic disease of man. Vector control and drug treatment have been the major defences against the disease, but environmental concerns and vector and parasite resistance have strongly curtailed the effectiveness of this strategy. Despite a large international effort, antimalarial vaccines have not been produced. It is therefore critical that a vaccine is developed and 'resistance-proof' antimalarial drugs are found. Such an effort would be greatly facilitated by improvement of our understanding of the mechanisms of host resistance and immunity to malaria. It is still not known why children die from malaria, when their siblings and peers are infected by the same strains and yet exhibit milder symptoms and survive. There are obvious genetic differences in populations from endemic areas, and perhaps these mutations -plus others yet to be found -offer protection to the 99 per cent of children who survive childhood malaria.
Mouse strains offer a valid model of human malaria. There are a number of different parasites infecting the laboratory mouse, and while none of these behaves like P. falciparum, the deadly strain of human malaria, they do model parts of the disease. There are also significant interstrain variations which have been exploited to study host responses. Therefore, the mouse model offers a powerful tool for dissecting and understanding the host response mechanism to malaria, and through comparative genomics it will be possible to identify the orthologous genes in humans.
Murine malaria parasites
The unequivocal malaria parasites of murine rodents fall into four groups: P. berghei, P. yoelii, P. vinckei and P. chabaudi. These four species are the most commonly used in the mouse model. The blood stages of the berghei group are morphologically indistinguishable and are notable for their marked predilection for immature erythrocytes in the blood of experimentally infected laboratory mice. This characteristic allows parasites of this group (P. berghei and P. yoelii sspp.) to be readily distinguished from P. vinckei sspp. and P. chabaudi sspp.
1,2 The P. berghei parasite is thought to be a monomorphic species. 3 The P.c. chabaudi (P.c.) species comprises two subspecies, P.c. chabaudi and P.c. adami. P.c. chabadi has been found in only two locations in Africa.
1,2 A full comparison of all of the stages of the life cycles of the two subspecies has not been made, and it is therefore not known if there are morphological differences between P.c. chabaudi and P.c. adami. The P. vinckei species comprises four subspecies with minor morphological differences.
1,4
The genetics of drug resistance Some of the early work on drug resistance was carried out in murine parasites. Pyrimethamine-resistant parasites have been selected from all murine malaria species -that is, P. berghei, 5, 6 P. yoelii,
7
P. chabaudi 8 and P. vinckei. 9 Genomewide scan studies in crosses between pyrimethamine-sensitive and -resistant lines of P. yoelii and P. chabaudi, respectively, showed that the resistant phenotype appeared to be controlled by a single locus. 7, 8 Subsequently, a mutation in the Dhfr gene was identified as a probable candidate gene underlying pyrimethamine resistance in P. falciparum.
10
Given that all P. yoelii isolates examined so far are innately chloroquine resistant, 11 P. chabaudi parasites have been selected for resistance to chloroquine -until recently the most widely used of all antimalarial compounds. It has been shown that the level of resistance in the chloroquineresistant clone is probably due to an accumulation of mutations at different loci, each contributing a low level of resistance. 12 No mutation was found in the murine parasite, however; the mechanism of resistance to this drug was elucidated through studying the human parasite itself. With current technology and tools, and with the availability of the genome sequence, 13 it will be possible to identify the drug-resistant genes in P. falciparum. The genetic background dictates either survival or death in the P. chabaudi model of murine malaria P. chabaudi has also been used to study resistance to sulphonamides. Sulphonamides are a family of drugs including sulfadoxine, which inhibits the enzyme dihydropteroate synthase. The combination of sulphadoxine and pyrimethamine (known as S/P or Fansidar) has been shown to be more effective than either drug used alone, and this has become the most widely used treatment for malaria after chloroquine. Resistance to S/P appeared in P. falciparum within a few years of its introduction into the field. Sulphonamide-resistant parasites have also been identified in P. berghei.
14 In general, sulfadiazine-resistant parasites have a reduced requirement for paminobenzoic acid (PABA), which suggests that resistant parasites could have acquired the ability to synthesise PABA de novo.
14,15 Again, however, the mutations giving rise to sulphonamide resistance were first identified in the human malarias.
Host innate immune response to murine malarias
Inbred mouse strains also differ markedly in their susceptibility to Plasmodium infection. 16 Parasites such as P. berghei and P. vinckei, and some P. yoelii and P. chabaudi strains, can cause lethal infections in mice. There are, however, substantial differences in the timing of death. For example, mice susceptible to the cerebral malarial syndrome caused by P. berghei die early on in infection and mice resistant to the cerebral effects die later from severe anaemia. Other isolates, including P. yoelii, P.c. chabaudi and P. vinckei petteri, cause infections in most strains of mice and may kill the mouse through severe acute anaemia or may resolve after an initial parasitaemia and are then either completely eliminated (in the case of P. yoelii) or have smaller patent recrudescences for several months (as in the cases of P.c. chabaudi and P. vinckei petteri).
17
For P.c. chabaudi it has been shown that the genetic background of the host controls the outcome of infection, with blood-stage infection in inbred mice following either a lethal or a non-lethal course in a host strain-dependent manner.
18,19 P. chabaudi is similar to P. falciparum in that it usual infects normocytes, undergoes partial sequestration (although predominantly in the liver and not in the brain) and, in resistant strains of laboratory mice, recovery from the acute primary parasitaemia is followed by one or more patent recrudescences. [19] [20] [21] Table 1 summarises the current collective information about the susceptibility of different inbred mouse strains after challenge with P. chabaudi (http://www.informatics.jax.org/). 23 and Fortin and colleagues. 24 Foote and colleagues 23 used two F2 resource populations in their genome-wide search for resistance QTL, which were developed by crossing one resistant strain, C57Bl/6, with two susceptible strains, SJL and C3H/He. This study found a locus on chromosome 9 (Mmu9) in both crosses, while an additional locus mapped to chromosome 8 (Mmu8) in the C57BL/6 3 C3H/He cross only. The two loci were shown to be associated with control of both host survival and peak parasitaemia. These loci have been named char1 (Mmu9) and char2 (Mmu8) for P. chabaudi resistance loci.
Fortin and colleagues 24 used a backcross (BC) strategy to map host response QTL and, in a C57Bl/6 (resistant) by A/J (susceptible) cross, identified two loci, mapping to chromosomes 8 (Mmu8) and 5 (Mmu5). The Mmu8 QTL overlapped with that reported by Foote and colleagues. 23 Furthermore, suggestive QTL mapped to chromosomes 15 (Mmu15) and 17 (Mmu17).
An additional study by Burt and colleagues 25 reported a significant QTL on chromosome 17 (Mmu17) which they named char3. This QTL was confirmed to be associated with clearance of parasites from the circulation later in infection. Female mice were used in these crosses because they are more resistant to P. chabaudi infection than are males.
26 Char3 mapped to the proximal end of Mmu17. The most well-known candidate region underlying this locus is the mouse major histocompatibility (MHC) locus, the H2 complex. The MHC locus is involved in many, if not all, host response loci to infectious disease and has been implicated in a differential response to malaria through association of the tumour necrosis factor-alpha gene with the response to malaria in humans. 27 Recently, Fortin and colleagues 28 have reported a host response QTL in P. chabaudi infection. This QTL mapped to chromosome 3 (Mmu3) and was designated char4. It was found to be associated with peak parasitaemia. A second suggestive linkage on chromosome 10 (Mmu10) shows an additive effect with char4 on peak parasitaemia on a segment of approximately 10 centimorgans on chromosome 3. The founders of the F2 resource population in this study were of a recombinant congenic strain (AcB55), which was shown to be highly resistant to malaria infection, and the susceptible (A/J) strain. The AcB55 strain was derived from AcB/BcA recombinant congenic strains, bred from malariasusceptible A/J and resistant C57BL/6 mice. Despite lower parasitaemia, AcB55 and another congenic strain, AcB61, showed significant pathology (splenomegaly, a low number of erythrocytes and a high reticulocyte concentration) when compared with the parental strains. 29, 30 Sequence analyses of char4 candidate genes revealed a mutant liver and red cell-specific pyruvate kinase allele (Pklr 269A ). Mutations in the gene encoding pyruvate kinase in humans can lead to haemolytic anaemia. It is not obvious how this mutation in mice leads to resistance to malaria, and work is ongoing to solve this issue.
Two major studies have been carried out to fine-map the location of char2: the production of char2-congenic mice 25 and the use of advanced intercross lines; 31 however, none of these studies have achieved the high resolution necessary to clone and identify the genetic factors that underline the variant. This might be due 32 This region shares homology with human chromosome 5q31-q33, which was linked to the control of P. falciparum blood infection levels in an independent study. 33 Thus, the same locus seemed to play a role in the control of parasite levels in both hosts and it is possible that a common resistance gene exists in both species.
Cerebral malaria is a major cause of morbidity and mortality in Africa, especially in children. 34 It involves an immunopathophysiological process caused by P. falciparum in humans and P. berghei ANKA in rodents. It is characterised pathologically in humans as a dense sequestration of parasitised erythrocytes in cerebral blood vessels. [35] [36] [37] Inbred mouse strains respond differently to cerebral malaria after infection with P. berghei. [38] [39] [40] This is summarised in Table 1 (from http://www.informatics.jax.org/). Furthermore, Bagot and colleagues 41 have recently reported the development of new inbred mouse strains derived from wild stock and found to be resistant to P. berghei infection.
Recently, Nagayasu and colleagues 42 published the first results of a genomewide scan for resistant QTL to P. berghei infection using an F2 intercross population generated from moderate resistant, DBA/2, and susceptible, C57BL/6, mouse strains. They showed a single significant QTL associated with resistance on chromosome 18 (Mmu18). Additional suggestive QTL were also reported on chromosomes 5 (Mmu5), 8 (Mmu8) and 14 (Mmu14). Sex-specific QTL were seen when the sexes were analysed separately. Male mice showed a significant linkage on chromosome 18 (Mmu18), and suggestive linkage on chromosomes 11 (Mmu11) and 19 (Mmu19). Female mice showed a suggestive QTL on chromosomes 18 (Mmu18) and 5 (Mmu5). This report demonstrated that female mice were more susceptible than males. This is in contrast to results with P .chabaudi infection. Four loci have been reported, in three different studies, to be involved in the development of murine cerebral malaria induced by P. berghei ANKA. [42] [43] [44] Infection with the erythrocytic stage of the reticulocytotropic rodent malaria P. yoelii leads to generally non-lethal infection from which mice recover and are subsequently resistant to rechallenge. 45 Accordingly, levels of susceptibility are evaluated by the degree of parasitaemia and anaemia, rather than lethality. Mouse strains C57BL/6, BALB/c and SWR/J develop greater parasitaemia and anaemia after infection than do AKR/J or DBA/ 2J. 46 Several studies have suggested that susceptibility to infection by P. yoelii is under a multigenic control mechanisms and that genes which influence P. yoelii infection do not influence the outcome of infection by other parasite strains. 46, 47 In an early study, it was shown that the BALB/c.D2 congenic mouse strain (congenic for the mtv-7 locus, located on the distal region of chromosome 1) exhibits an altered susceptibility phenotype to the parental BALB/c line, suggesting that this locus is involved in resistance to P .yoelii infection. 48 Ohno and colleagues 49 have reported the results of a genome-wide search for resistance QTL to P. yoelii infection. Their study was conducted in a BC resource population. The BC population was generated by crossing the F1 of the susceptible mouse strain NC/Jic and the resistant strain 129/SvJ, with NC/Jic ([NC/Jic 3 129/SvJ] 3 NC/Jic). The results showed a single QTL, controlling host survival and peak parasitaemia, mapping to chromosome 9 (Mmu9), within the locus of char1. These authors P. berghei produces a cerebral-like malaria syndrome in mice
Response to berghei and yoelii malarias is also under multigenic control Resistance to disease by T. congolense in cattle is strain dependent proposed that this QTL may represent a ubiquitous locus controlling susceptibility to murine malaria. Table 2 summarises all the significant genetic loci linked to the host response to P. chabaudi, P. yoelii and P. berghei parasites.
TRYPANOSOMIASIS
Trypanosomiasis is endemic in a 7 million km 2 area of Africa and is one of the major constraints to livestock productivity, with 60 million cattle at risk of infection. 50 Although humans are directly affected by some species of trypanosome, it may be argued that people are most severely affected by the trypanosomes which infect their livestock, and it is here that research on innate resistance mechanisms has been focused. The disease in cattle is largely due to the tsetse fly-transmitted Trypanosoma congolense and costs an estimated $1.3bn per annum. 51 The biology of trypanosomiasis has been studied in some detail in mice and cattle; however, the systemic nature of this extracellular pathogen has made it difficult to identify the mechanisms responsible for the control of the infection. Critically, although the parasite can be maintained in culture, there is no satisfactory in vitro model of the response to infection.
While most breeds of cattle are highly susceptible to trypanosomiasis, it has been known for many years that certain breeds of domestic ruminants show a remarkable resistance to the consequences of infection. This has been termed 'trypanotolerance' because the host tolerates the presence of parasites while apparently controlling levels of parasitaemia and, critically, without showing the severe anaemia and reduced growth rate characteristic of infection in susceptible hosts. 52 A unique F 2 resource population derived from trypanotolerant N'Dama bulls crossed with susceptible Boran cows revealed nine QTL influencing the outcome of infection with T. congolense, with a confidence such that more than 90 per cent will have real effects. 53 This cattle-based study was extremely expensive, however, and identified QTL with a relatively low resolution. Nevertheless, trypanotolerance research 44 has, from the start, gained value by comparison with the mouse system, and this synergy continues to grow as the mouse becomes an increasingly powerful model for functional genomics. The various inbred strains of mice show a range of responses to trypanosome infection. 54 Trypanotolerance resistance QTL were first identified in mice by Kemp et al., 55 and this is probably the first reported localisation of QTL determining resistance to an infectious disease by genome scanning. This study was conducted in two separate F2 intercross populations. One was a cross between resistant C57BL/6J (B6) and susceptible BALB/c (B) strains the other between A/J (A) and B6 strains. Mice were challenged with T. congolense (which is the most important trypanosome infecting livestock) and QTL mapping was based on a single trait -survival time. This study revealed three QTL influencing survival time in both crosses, which were termed Tir1, -2 and -3.
Subsequently, the use of advanced intercross generations of mice 56 allowed significantly improved mapping resolution due to the increased number of recombination events. Again, B6 3 A and B6 3 B intercrosses were used independently, but this time as an F6. This led to a minimum 95 per cent confidence interval of around 1 centimorgan for the QTL of largest effect (Tir1) and also resolved Tir 3 into three separate QTL. 57, 58 Clapcott et al. 59 also showed evidence that Tir1 (on Chr17) shows a parent-oforigin effect. In this study, four backcross populations derived from the C57BL/6J and BALB/c parental strains were challenged with T. congolense. The two populations with F1 fathers and BALB/c mothers had a significantly higher overall survival rate than the two populations with BALB/c fathers and F1 mothers. Analysis of these populations revealed all the expected QTL, except that the Tir1 QTL was essentially absent in the backcross in which the resistant allele was inherited from the female F1.
The murine mapping data may now be integrated with the bovine mapping data in order to illuminate both systems. In doing this, however, the critical unknown factor is how far the mouse is a 'model' of the cow, or indeed human, system. There are important differences between murine and bovine tolerance; resistant cattle normally show little, if any, disease and remain healthy and productive despite the presence of parasites. By contrast, even 'resistant' mouse strains usually succumb eventually, although they have mean survival times very much longer than 'susceptible' strains. It is clear, therefore, that there are important differences between the systems; however, the assumption is that any mechanism which allows one mouse to survive twice as long as another mouse is worthy of investigation. It was certainly not expected that the same genes would underlie QTL in different species, but it is expected that an understanding of mechanisms modulating disease response in one system will be informative in another species.
WHERE ARE WE NOW, AND WHERE ARE WE HEADING, WITH THE USE OF MURINE MODELS?
At face value, the genetic use of mouse models of malaria and trypanosomes have not told us an enormous amount about the biology of the host response to malaria. Only one gene has been described which mediates the host response to malaria, although there have been a number of response QTL identified and there is hope that these will teach us something about the host response to disease. This statement must, however, be seen in the more general context of mapping QTL in the mouse. There has been a very low rate of conversions of QTL identification to gene identification. This is because, despite the publication of the sequence of the mouse genome, 60 narrowing the intervals is still arduous and many identified QTL are often genetically complex. There is, however, hope on the horizon. There seems to be only a limited number of haplotypes in the laboratory strains of mice and, in each strain, these haplotypes occupy a reasonably sizeable stretch of DNA. It is therefore possible to deduce the resistant and susceptible haplotypes by examining multiple mouse strains. The question of locus heterogeneity will still complicate this approach. Other approaches to mapping QTL include large numbers of advanced recombinant congenic lines in which recombinant intervals will be small and the large numbers of lines will enable accurate localisation of the QTL.
In the more immediate future, many groups which have been generating congenic lines for the known QTL will be presenting their results, and the results from an examination of the biology of these lines will also become available. These could give some interesting insights into associated phenotypes ahead of the identification of the underlying genes.
The development of microarray technology, with the spotting of mouse genes onto chips, is presently being used to follow changes in the expression of all mouse genes as a response to infection. In particular, it is possible to contrast the response of resistant and susceptible genotypes. It is hoped that this will illuminate the differences between the cascade of events in the two systems and determine where genes within the QTL participate in such pathways.
Following completion of the P. falciparum and T. brucei genome sequence and their imminent annotation and publication, 13 ,61 now seems an appropriate time to study the switching on and off of genes in host and parasite following an infection. This information will open the doors for understanding the communication which must occur between host and parasite. Without doubt, the new era of functional genomics and proteomics will provide a great opportunity for researchers to understand and rescue these diseases.
Another interesting technique which has received much interest recently is the use of ENU mutagenesis 62 to generate genome-wide mutations and to screen for these mutations using a phenotype-based screen. This has not yet been published for an infectious disease, but a slight change to the normal protocol of looking for new phenotypes would be to find suppressor mutations using a lethal malarial infection as the index phenotype. This would identify novel mutations which would be able to prevent the lethality of infection. The genes mutated in such a screen would then be ideal candidates for host-directed therapy. Such therapy would mimic nature's own response, the generation of mutations in the human genome which are common in endemic regions and which protect against disease, and which, in many cases, have done so successfully for many millennia. Genes identified through the ENU mutagenesis would be targets for pharmacological intervention and would be refractory to the development of resistance by the parasite because they would not be under the genetic control of the parasite.
Finally, the steady rise in the number of mapped QTL in mice, and in other species, is beginning to provide useful additional information. There are frequent examples of QTL affecting a range of traits which have overlapping locations. For example, a QTL associated with resistance to Leishmania 63 overlaps the trypanosometolerance QTL Tir1 on Chr17. QTL associated with many physiological and immune functions are also being mapped and many are likely to represent the same underlying polymorphism. There remains a great deal of difficulty in the analysis of this information, however, because there is no consistency in the way in which it is reported and stored on databases, although a number of studies are now addressing this issue and it is likely that tools for systematic alignment of multiple QTL are imminent.
Congenic lines and microarray analysis may aid in the identification of host-response genes Host-directed therapies may mimic the effect of genetic resistance in future therapeutics
